Insights

Gathering insights about Glue…

Similar companies to Glue

Glue Tech Stack

Glue uses 8 technology products and services including Amazon S3, Font Awesome, Google Fonts API, and more. Explore Glue's tech stack below.

Amazon S3
Content Delivery Network
Font Awesome
Font Scripts
Google Fonts API
Font Scripts
Twemoji
Font Scripts
React
Javascript Frameworks
HubSpot
Marketing Automation
Java
Programming Languages
Cloudflare Bot Management
Security

Media & News

BETTY NAMED CREATIVE AGENCY OF RECORD FOR GORILLA GLUE
Agency will partner with Gorilla Glue on creative campaigns that build on the brand's toughness equity MINNEAPOLIS , Nov. 19, 2025 /PRNewswire/ -- Betty, a Quad agency, today announced it has been named the creative agency for Gorilla Glue, a leader in tough adhesives. Gorilla Glue joins the growing roster of brands turning to Betty for strategic, imaginative creative that drives business growth.
Nov 19, 2025 | www.prnewswire.com
Monte Rosa Therapeutics Presents Preclinical Data at AHA Scientific Sessions 2025 on the Potential of MRT-8102, a NEK7-directed Molecular Glue Degrader, to Treat Cardiovascular and Cardiometabolic Diseases
Data support NEK7 as a potential novel and differentiated therapeutic approach to modulate the NLRP3 inflammasome in multiple cardiovascular and cardiometabolic diseases, including pericarditis and atherosclerosis Initial data from a Phase 1 study of MRT-8102 in healthy volunteers and elevated CVD-risk subjects on track for first half of 2026 Poster presentation on November 8 at 10:30 a.m. CST BOSTON, Nov. 08, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the company will present preclinical data on the potential of MRT-8102, a first-in-class, NEK7-directed MGD for inflammatory diseases driven by the NLRP3 inflammasome, at the American Heart Association's Scientific Sessions 2025, held November 7-10 in New Orleans, LA.
Nov 08, 2025 | www.globenewswire.com
Monte Rosa Therapeutics (GLUE) Reports Q3 Loss, Tops Revenue Estimates
Monte Rosa Therapeutics (GLUE) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to a loss of $0.29 per share a year ago.
Nov 06, 2025 | www.zacks.com
Monte Rosa Therapeutics Announces Third Quarter 2025 Financial Results and Business Updates
Second agreement signed with Novartis to develop novel degraders for immune-mediated diseases, providing upfront payment of $120 million plus option maintenance payments, and eligibility for option exercise payments, milestones, and tiered royalties Phase 1 study of NEK7-directed MGD MRT-8102 underway, investigating a potential novel approach to treat inflammatory diseases driven by the NLRP3 inflammasome; initial readout including data from high-CVD risk cohort on track for H1 2026 VAV1-directed MGD MRT-6160 advancing toward anticipated initiation of multiple Phase 2 studies in immune-mediated diseases Phase 1/2 study of GSPT1-directed MGD MRT-2359 advancing in heavily pretreated, metastatic castration-resistant prostate cancer (mCRPC) patients; additional results expected by year-end Strong cash position expected to fund operations through 2028, enabling multiple anticipated proof-of-concept clinical readouts across the portfolio BOSTON, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today reported business highlights and financial results for the third quarter ended September 30, 2025. “With three programs in clinical development and a highly productive drug discovery engine creating additional future opportunities, we are building a leading protein degradation company innovating in the molecular glue degrader space,” said Markus Warmuth, M.D.
Nov 06, 2025 | www.globenewswire.com
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that Markus Warmuth, M.D., Chief Executive Officer, will participate in fireside chats at the following investor conferences: Guggenheim 2nd Annual Healthcare Innovation Conference (Boston, MA) – November 10, 2025, at 11:30 a.m.
Nov 03, 2025 | www.globenewswire.com
Brighton Jones LLC Acquires New Stake in Monte Rosa Therapeutics, Inc. $GLUE
Brighton Jones LLC bought a new position in shares of Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 10,559 shares of the company's stock, valued at approximately $48,000. A number of other institutional investors have
Nov 02, 2025 | www.defenseworld.net
Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2025 on the Potential of MRT-6160, a VAV1-directed Molecular Glue Degrader, to Treat Immune-mediated Diseases
MRT-6160 inhibited disease pathology, including proteinuria, lymphadenopathy, skin lesion formation, autoantibody production, and organomegaly, in a spontaneous autoimmune disease mouse model Data support the potential of MRT-6160 to address multiple rheumatic autoimmune and inflammatory diseases, including Sjögren's disease, systemic lupus erythematosus, and rheumatoid arthritis Poster presentation on October 26th at 10:30 am CDT BOSTON, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the company will present preclinical data on the potential of MRT-6160, a rationally designed molecular glue degrader (MGD) that selectively degrades VAV1, to treat multiple autoimmune and inflammatory diseases, at ACR Convergence 2025, held October 24-29 in Chicago, IL. “In a preclinical autoimmune disease model characterized by chronic inflammation, autoantibody production, and multi-organ involvement, administration of MRT-6160 resulted in broad activity across an array of disease markers, including attenuated autoantibody levels and reduced skin and kidney pathology,” said Sharon Townson, Ph.D.
Oct 24, 2025 | www.globenewswire.com

Glue's Email Address Formats

Glue uses at least 1 format(s):

Glue Email Formats	Example	Percentage
First.Last@glue.work	John.Doe@glue.work	48%
First@glue.work	John@glue.work	2%
First.Last@glue.work	John.Doe@glue.work	48%
First@glue.work	John@glue.work	2%

Frequently Asked Questions

Where is Glue's headquarters located?

Glue's main headquarters is located at Meritullinkatu 11, Helsinki, Southern Finland 00170, FI. The company has employees across 3 continents, including EuropeAsiaNorth America.

What is Glue's stock symbol?

Glue is a publicly traded company; the company's stock symbol is GLUE.

What is Glue's official website and social media links?

Glue's official website is glue.work and has social profiles on LinkedIn Crunchbase.

What is Glue's NAICS code?

Glue's NAICS code is 5112 - Software Publishers.

How many employees does Glue have currently?

As of October 2025, Glue has approximately 11 employees across 3 continents, including EuropeAsiaNorth America. Key team members include Executive Chairman: D. S.. Explore Glue's employee directory with LeadIQ.

What industry does Glue belong to?

Glue operates in the Software Development industry.

What technology does Glue use?

Glue's tech stack includes Amazon S3Font AwesomeGoogle Fonts APITwemojiReactHubSpotJavaCloudflare Bot Management.

What is Glue's email format?

Glue's email format typically follows the pattern of First.Last@glue.work. Find more Glue email formats with LeadIQ.

How much funding has Glue raised to date?

As of October 2025, Glue has raised $3.9M in funding. The last funding round occurred on Nov 14, 2019 for $3.9M.

When was Glue founded?

Glue was founded in 2017.

Glue

Software DevelopmentFinland11-50 Employees

Glue is a virtual collaboration platform for teams who need remote meetings to be as great as face-to-face meetings.
Glue brings remote teams together to learn, share, plan and create. Combining the best in immersive 3D graphics, virtual reality and cloud computing technology, Glue empowers teams everywhere to maximize their collaborative potential.

Company Overview

Headquarters: Meritullinkatu 11, Helsinki, Southern Finland 00170, FI
Website: glue.work
Stock Symbol: GLUE
NAICS Code: 5112 - Software Publishers
Founded: 2017
Employees: 11-50

Media & News

Funding & Financials

$3.9M
Glue has raised a total of $3.9M of funding over 2 rounds. Their latest funding round was raised on Nov 14, 2019 in the amount of $3.9M.
$1M
Glue's revenue is estimated to be in the range of $1M

Funding & Financials

$3.9M
Glue has raised a total of $3.9M of funding over 2 rounds. Their latest funding round was raised on Nov 14, 2019 in the amount of $3.9M.
$1M
Glue's revenue is estimated to be in the range of $1M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

Insights

Similar companies to Glue

Latch

Level

August

Samsung

Kwikset

LOCKLY

Glue Tech Stack

Media & News

BETTY NAMED CREATIVE AGENCY OF RECORD FOR GORILLA GLUE

Monte Rosa Therapeutics Presents Preclinical Data at AHA Scientific Sessions 2025 on the Potential of MRT-8102, a NEK7-directed Molecular Glue Degrader, to Treat Cardiovascular and Cardiometabolic Diseases

Monte Rosa Therapeutics (GLUE) Reports Q3 Loss, Tops Revenue Estimates

Monte Rosa Therapeutics Announces Third Quarter 2025 Financial Results and Business Updates

Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences

Brighton Jones LLC Acquires New Stake in Monte Rosa Therapeutics, Inc. $GLUE

Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2025 on the Potential of MRT-6160, a VAV1-directed Molecular Glue Degrader, to Treat Immune-mediated Diseases

Glue's Email Address Formats

Frequently Asked Questions

Where is Glue's headquarters located?

What is Glue's stock symbol?

What is Glue's official website and social media links?

What is Glue's NAICS code?

How many employees does Glue have currently?

What industry does Glue belong to?

What technology does Glue use?

What is Glue's email format?

How much funding has Glue raised to date?

When was Glue founded?

Glue

Company Overview

Media & News

BETTY NAMED CREATIVE AGENCY OF RECORD FOR GORILLA GLUE

Monte Rosa Therapeutics Presents Preclinical Data at AHA Scientific Sessions 2025 on the Potential of MRT-8102, a NEK7-directed Molecular Glue Degrader, to Treat Cardiovascular and Cardiometabolic Diseases

Monte Rosa Therapeutics (GLUE) Reports Q3 Loss, Tops Revenue Estimates

Funding & Financials

Funding & Financials

Company Leadership

Employee Directory

Ready to create more pipeline?

Ready to create more pipeline?